Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
LOADING
|||
Revenue Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year revenue growth rate
Latest
142.43%
↑ 1105% above average
Average (39q)
11.82%
Historical baseline
Range
High:142.43%
Low:-54.33%
CAGR
+5.2%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | 142.43% |
| Q2 2025 | 5.06% |
| Q1 2025 | 5.89% |
| Q4 2024 | -17.37% |
| Q3 2024 | 24.76% |
| Q2 2024 | 34.07% |
| Q1 2024 | 10.24% |
| Q4 2023 | -14.50% |
| Q3 2023 | 24.66% |
| Q2 2023 | -40.05% |
| Q1 2023 | 62.61% |
| Q4 2022 | -54.33% |
| Q3 2022 | 18.14% |
| Q2 2022 | 37.27% |
| Q1 2022 | -49.61% |
| Q4 2021 | 11.78% |
| Q3 2021 | -23.43% |
| Q2 2021 | 53.54% |
| Q1 2021 | -21.20% |
| Q4 2020 | 67.25% |
| Q3 2020 | 1.03% |
| Q2 2020 | 24.91% |
| Q1 2020 | 22.80% |
| Q4 2019 | 8.85% |
| Q3 2019 | -0.72% |
| Q2 2019 | -42.54% |
| Q1 2019 | -27.03% |
| Q4 2018 | 30.50% |
| Q3 2018 | -49.29% |
| Q2 2018 | 60.34% |
| Q1 2018 | 11.28% |
| Q4 2017 | 51.20% |
| Q3 2017 | 19.22% |
| Q2 2017 | -4.35% |
| Q1 2017 | -23.35% |
| Q4 2016 | 76.63% |
| Q3 2016 | 10.75% |
| Q2 2016 | -34.16% |
| Q1 2016 | 39.90% |
| Q4 2015 | 19.72% |